Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

13.95
-0.0400-0.29%
Post-market: 13.950.00000.00%18:31 EDT
Volume:2.21M
Turnover:31.36M
Market Cap:2.03B
PE:-5.22
High:14.66
Open:14.49
Low:13.83
Close:13.99
Loading ...

Denali Therapeutics Inc - Expects 10%-15% Increase in Cash Operating Expenses for 2025

THOMSON REUTERS
·
28 Feb

Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
10 Feb

DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study

Zacks
·
07 Feb

Denali Therapeutics announces primary analysis of Phase 1/2 study in MPS II

TIPRANKS
·
07 Feb

BRIEF-Denali Therapeutics Announces Primary Analysis & Long-Term Follow-Up Of Phase 1/2 Study In Hunter Syndrome With Tividenofusp Alfa

Reuters
·
07 Feb

Denali Therapeutics Inc: Long-Term Safety Data Demonstrate That Tividenofusp Alfa Was Generally Well Tolerated

THOMSON REUTERS
·
07 Feb

Denali Therapeutics: Tividenofusp Alfa U.S. Launch Preparation Ongoing to Deliver Tividenofusp Alfa to Families With Mps Ii in Late 2025 or Early 2026

THOMSON REUTERS
·
07 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-up of Phase 1/2 Study in Hunter Syndrome (Mps Ii) With Tividenofusp Alfa

THOMSON REUTERS
·
07 Feb

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

GlobeNewswire
·
07 Feb

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (Mps Ii) and Transportvehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 Worldsymposium™

THOMSON REUTERS
·
30 Jan

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

GlobeNewswire
·
30 Jan

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Zacks
·
21 Jan

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)

TIPRANKS
·
16 Jan

BRIEF-Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities

Reuters
·
13 Jan

Denali Therapeutics Inc: Anticipates Its Cash Runway Will Extend Into 2028

THOMSON REUTERS
·
13 Jan

Denali Therapeutics Inc: Preparing for Commercial Launch of Tividenofusp Alfa for Hunter Syndrome in Late 2025 or Early 2026

THOMSON REUTERS
·
13 Jan

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

GlobeNewswire
·
13 Jan

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation

Zacks
·
10 Jan

Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment

MT Newswires Live
·
08 Jan